“`html
Institutional Investors Adjust Holdings in Avadel Pharmaceuticals
Several institutional investors have recently adjusted their holdings in Avadel Pharmaceuticals (AVDL), signaling potential shifts in confidence regarding the company’s future performance. These moves, reported through various regulatory filings, provide insights into how major players in the financial market view Avadel’s prospects. As of january 16, 2026, these adjustments include both increased and decreased positions.
Recent Investor Activity
- BlackRock: Securities and Exchange Commission filings indicate that BlackRock, a major asset management firm, holds a 6.93% stake in avadel Pharmaceuticals as of the latest reporting period. Investing.com reported on this significant holding.
- UBS O’Connor:
Keep reading